Clarient Cancer Diagnostics
When confronted with cancer, a physician has to pick from the more than 400 available therapies. But how do you pick the one that holds the most promise?
Founded to make sophisticated diagnostic techniques available to breast cancer patients in rural areas, Clarient is now helping to realize the vision of transforming cancer into a treatable chronic disorder.
Today, individualized disease management is possible due to user-friendly and inexpensive diagnostics. Thanks to our deepening knowledge of DNA as a result of the Human Genome Project, along with the discovery of molecular-based therapeutics, doctors can now predict a patient’s response to specific therapies.
Molecular medicine is transforming the entire spectrum of disease management—from detecting a cancer in its early stages to characterizing its evolution and predicting an individual patient’s response to therapies.
Clarient was created six years ago in an attempt to provide the same level of diagnostic information and care to breast cancer patients, regardless of whether they live in remote rural areas or close to major academic medical centers. By providing access to sophisticated molecular pathology testing services, Clarient allows physicians to make a complete assessment of a particular manifestation of the disease and use their understanding of the patient’s individual biological makeup to prescribe the most appropriate treatment.
Now part of GE Healthcare, Clarient is expanding the benefits of molecular pathology testing services beyond breast cancer to a broad array of other cancers. Having served more than 500,000 patients in the U.S. to date, Clarient is beginning to offer its capabilities worldwide.
